Navigation Links
CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Clinical Safety and Efficacy
Date:9/30/2010

"CYPHER remains an essential treatment option for today's interventional cardiologist considering its unsurpassed clinical safety and efficacy proven out to 10 years and the 7 extended indications (e.g. diabetes, AMI, multi vessel disease) in which CYPHER(R) stent specifically demonstrated superior outcomes," said Rogers.

Notes to Editors:

CYPHER(R) Sirolimus-eluting Coronary Stent in detail

The CYPHER(R) stent releases a unique anti-inflammatory and anti-proliferative-type medicine, sirolimus, into the artery wall over a period of 90 days. The sirolimus drug helps limit the overgrowth of normal cells while the artery heals. The CYPHER(R) Stent has a unique closed-cell design that allows the medicine to be distributed more evenly across the treated area and that helps to keep the arteries open and the blood flowing to the heart, reducing the chance of re-intervention in the treated area. Eighty percent (80%) of the sirolimus drug is released during the first 30 days. The rest is released by the end of 90 days.

About CYPHER(R) stent studies

The CYPHER(R) Stent is the most studied drug-eluting stent in the world, it has a proven safety profile out to 10 years and has been used in nearly 4 million patients worldwide. Today, with more than 9.000 citations on PubMed, CYPHER(R) Sirolimus-eluting Coronary Stent is recognized as having the most in depth clinical data, which marked it out as the most effective drug-eluting stent available today with a clinical safety profile presenting minimal risks. CYPHER's(R) body of clinical evidence is completely unmatched by any other drug-eluting stent. The CYPHER(R) Stent has consistently proven to control late loss across all vessel sizes and across a broad patient population, even in the most complex types of patients such as patients with diabetes and acute myocardial infarction. In fact, the CYPHER(R) Stent has shown more than 70% risk reduction in target lesion revascularization (TLR) whe
'/>"/>

SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
2. Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent
3. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
4. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
5. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
6. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
9. Pre-clinical Data Show OrbusNeichs Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
10. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
11. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., previously ... members to its Board of Directors, enhancing executive ... the company, a leading licensed producer of medicinal ... Bedrocan has 13 years, experience in producing and ... countries, including Canada. As previously ...
(Date:8/21/2014)... -- Cyberonics, Inc. (NASDAQ: CYBX ) today announced results ... Quarterly highlights 1   Operating results for the ... of fiscal 2014, and other achievements, include: , Worldwide ... , Strong international net sales of $13.2 million, an ... U.S. net product sales reached a new high of $58.8 ...
(Date:8/21/2014)... , Aug. 21, 2014 Asterias Biotherapeutics, Inc. ... field of regenerative medicine, announced today the appointments of ... Company,s newly expanded Board of Directors. With these additions, ... three of whom are independent. Andy ... with emerging growth companies. He is currently Managing Director ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
(Date:8/21/2014)... on her body in terms of how it can ... complete human being with thoughts and feelings. While objectification ... how does it affect individual romantic relationships? New research ... SAGE journal, finds that more objectification of a female ... pressure and coercion., Researchers Laura R. Ramsey and Tiffany ...
(Date:8/21/2014)... New York, New York (PRWEB) August 21, 2014 ... allege the blood thinner caused patients to suffer uncontrollable ... in U.S. courts, Bernstein Liebhard LLP reports. According to ... August 14th in U.S. District Court, Easter District of ... who died due to a bleeding event that was ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 According to ... “Home Audio Equipment (Product Types - Home Theatre in-a-box, ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... at USD 15.94 billion in 2012 and is expected ... a CAGR of 3.7% from 2013 to 2019. Europe ...
(Date:8/21/2014)... American Addiction Centers, a leading national provider ... drug and/or alcohol addiction, has been named to the ... , The company is ranked 7th on the “Top ... on the list in the “Nashville Metro Area” sub-category. ... Addiction Centers (AAC) ascended to number 474 on the ...
(Date:8/21/2014)... Sasha is a 10 year old Alaskan malamute, and ... older, and is having trouble getting up and down, and ... an owner who purchased a Butler Mobility Inclined Platform Wheelchair ... no longer get up and down the stairs from main ... had tried a stair lift, but had to transfer from ...
Breaking Medicine News(10 mins):Health News:Objectification in romantic relationships related to sexual pressure and coercion 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 2Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 3Health News:American Addiction Centers Named to Inc. 500 List Recognition for Three-Year Sales Growth of 995% 2Health News:Sasha Gets a Butler Mobility Inclined Platform Lift 2
... Haiti , Jan. 19 One week later, ... of delivering aid in the aftermath of the Haiti ... aid is beginning to get through, the impact of the ... combined with a destroyed office and warehouse and the loss ...
... , JACKSONVILLE, Fla. and DES ... Inc. ( www.USPreventiveMedicine.com ) will partner with the Iowa Chronic Care ... not yet eligible for Medicare reduce health risks and live longer, ... equal amounts by a grant/cooperative agreement from the Centers for Disease ...
... PHILADELPHIA , Jan. 19 Independence Blue ... been promoted to chief marketing executive. Taylor will report to ... Independence Blue Cross. , As chief marketing executive, Taylor ... Cross (IBC) and two of the company,s third-party administrators:  Independence ...
... , , PHILADELPHIA , Jan. ... Paul A. Tufano has assumed an expanded role of senior ... continue to report to IBC president and CEO Joseph A. ... counsel since November 1999 when he joined IBC. , ...
... , ... Lindt Chocolate , the world,s leading producer of premium chocolate, announces it ... Autism program. For the second year, Lindt will honor ordinary individuals ... home or community.  The Lindt Unsung Heroes of Autism program is part ...
... Providence, RI New research at Rhode Island Hospital has ... brain tumors which, once diagnosed, offer a poor prognosis and ... naturally-occurring hormone combined with chemotherapy, researchers were able to inhibit ... study and their findings are published in the Journal ...
Cached Medicine News:Health News:Haiti Earthquake: One Week Later, Aid Agencies Facing Challenges 2Health News:Iowa Farm Bureau Introduces Bold Initiative to Improve Health Care for Rural Iowans 2Health News:Iowa Farm Bureau Introduces Bold Initiative to Improve Health Care for Rural Iowans 3Health News:Iowa Farm Bureau Introduces Bold Initiative to Improve Health Care for Rural Iowans 4Health News:Taylor Promoted to Independence Blue Cross Chief Marketing Executive 2Health News:Taylor Promoted to Independence Blue Cross Chief Marketing Executive 3Health News:Independence Blue Cross Announces New, Expanded Role For Key Executive 2Health News:Independence Blue Cross Announces New, Expanded Role For Key Executive 3Health News:Autism Speaks and Lindt Seeking Nominations for 'Lindt Unsung Heroes of Autism' 2Health News:Autism Speaks and Lindt Seeking Nominations for 'Lindt Unsung Heroes of Autism' 3Health News:Autism Speaks and Lindt Seeking Nominations for 'Lindt Unsung Heroes of Autism' 4Health News:Researchers find a treatment for deadly brain tumor 2
...
...
... Bigliani/Flatow shoulder allows for the restoration ... of shoulder replacement surgery. Backed by ... decades of experience, the Bigliani/Flatow Shoulder ... natural shoulder's mobility, balance, and stability ...
... Simplified shoulder replacement system designed ... implantation. Multiple component combinations for ... revision length porous titanium stems. ... of Bi-Polar shell diameters and ...
Medicine Products: